On the afternoon of March 24, Zhang Hongyu, Director of the hematology department of Peking University Shenzhen Hospital, and Dr. Li Zhenhai visited Shenzhen Cell Valley Biomedicine Co., Ltd. for exchange and visit. Professor Wang Jianxun, chief scientist of Shenzhen Cell Valley, and Sun Rui, vice minister of research and Development Department, warmly received and discussed the establishment of preclinical research cooperation on disease pathogenesis.

At the symposium, Professor Wang Jianxun introduced the main pipeline and main research direction of Shenzhen Cell Valley to Director Zhang Hongyu's team. Professor Wang Jianxun has been committed to epigenetics research since his doctoral study, and then entered the cell immunotherapy industry in the United States. He has set up an excellent technology research and development and industrialization team with GMP production experience in China. Subsequently, the two sides made an in-depth analysis based on the prospects and current pain points of CAR-T cell immunotherapy in the treatment of tumors, and conducted in-depth discussions and exchanges on related technical details such as the pathogenesis and treatment plan of Epstein Barr virus induced tumors.

Subsequently, Professor Wang Jianxun accompanied Director Zhang Hongyu and Dr. Li Zhenhai to visit the laboratory and gave a detailed introduction. The two sides expressed their willingness to establish in-depth scientific research cooperation in T cell epigenetics and cellular immunotherapy, closely integrate scientific research with clinical practice, apply to clinical practice and serve clinical practice, and contribute to the development of cell therapy.